Plain-English translation of NCT06589440 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called , given by mouth, combined with two immune-boosting drugs called botensilimab and balstilimab, which are given through an IV. The study wants to see if this three-drug combination can shrink or slow down advanced bowel cancer in people whose cancer has stopped responding to standard chemotherapy.
Most people with advanced bowel cancer of a specific type (called microsatellite stable) don't respond well to current immune therapies. This trial is testing whether combining this new treatment with two different immune drugs might work better for patients whose cancer has become resistant to previous treatments.
You likely qualify if…
You likely don't qualify if…
You would take the oral medication by mouth daily and receive the two IV medications on a regular schedule at the clinic. The study involves multiple visits for blood tests, imaging scans, and health check-ups to see how well the treatment is working and to monitor for any side effects. The trial is split into two groups depending on whether your cancer has spread to your liver, and your participation would continue as long as the treatment is helping and you're tolerating it well.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States